Treatment methods of triphenyl calcilytic compounds

A method of treating an autosomal dominant hypocalcemia type 1 (ADH1) comprising administering to a subject in need thereof a compound represented by formula (I):

• or a solvate, a hydrate, a pharmaceutically acceptable salt, or a combination thereof, according to one or more dosing regimens comprising a first dosing regimen, a second dosing regimen, and/or a third dosing regimen,
• wherein:
• 1) the first dosing regimen comprises administering a first therapeutically effective amount of the compound or the solvate, hydrate, pharmaceutically acceptable salt, or combination thereof, wherein the first therapeutically effective amount increases a blood calcium concentration (cCa) up to a maximum cCa of about 10.5 milligrams per deciliter (mg/dL);
• 2) the second dosing regimen comprises administering a second therapeutically effective amount of the compound or the solvate, hydrate, pharmaceutically acceptable salt, or combination thereof, wherein the second therapeutically effective amount titrates the blood calcium concentration (cCa) to a range of about 7.5 mg/dL to about 10.5 mg/dL;
• and
• 3) the third dosing regimen comprises administering a third therapeutically effective amount of the compound or the solvate, hydrate, pharmaceutically acceptable salt, or combination thereof, wherein the third therapeutically effective amount maintains the blood calcium concentration (cCa) in a range of about 7.5 mg/dL to about 10.5 mg/dL for a period of at least 12 weeks.